Ozempic

News

Novo Nordisk’s chief executive Lars Fruergaard Jørgensen

Novo Nordisk CEO agrees to testify on semaglutide pricing

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabete

News

Obesity drugs could bankrupt US healthcare, says Sanders

A report issued by the office of US Senator Bernie Sanders has claimed that the high prices being charged for new GLP-1 agonist-based obesity therapies like Novo Nordisk’s

News

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU me

News

Novo Nordisk looks set to add another string to Ozempic bow

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabete

News

Could Novo-Catalent deal face antitrust hurdles?

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities

News

Novo Nordisk tackles supply issues with $11bn Catalent deal

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging

Novo Nordisk CEO agrees to testify on semaglutide pricing

Obesity drugs could bankrupt US healthcare, says Sanders

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

Novo Nordisk looks set to add another string to Ozempic bow

Could Novo-Catalent deal face antitrust hurdles?

Novo Nordisk tackles supply issues with $11bn Catalent deal

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Ozempic

Editor's Picks